Dunad Therapeutics

Dunad Therapeutics

Biotechnology Research

Transformational Therapies Targeting Protein Degradation

About us

Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted oral protein degradation therapies. Dunad’s platform enables selective degradation via direct target modification using tunable mono-valent small molecules, allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Cambridge
Type
Privately Held
Founded
2020
Specialties
protein degradation, CNS disease, and Oncology

Locations

Employees at Dunad Therapeutics

Updates

Similar pages

Browse jobs

Funding